The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?

Area of Science:

• Oncology
• Radiotherapy
• Medical Physics

Background:

• Oligoprogressive disease presents a challenge in metastatic cancer management, where limited progression occurs despite systemic therapy.
• Targeted treatments, while effective, can lead to acquired resistance, necessitating novel therapeutic strategies.
• Local ablative therapy is being explored to address these specific progressing sites.

Purpose of the Study:

• To review the current evidence for local ablative therapy in managing oligoprogression in metastatic patients on targeted treatments.
• To discuss the role of stereotactic body radiotherapy (SBRT) in this context.
• To highlight the need for prospective data and ongoing clinical trials.

Main Methods:

• Review of retrospective clinical studies and case series.
• Analysis of treatment outcomes, toxicity, and survival data.
• Discussion of SBRT techniques and principles for oligoprogression.

Main Results:

• Retrospective data suggest that local ablative therapy, particularly SBRT, can be effective in controlling oligoprogressive disease.
• This approach may allow for the continuation of systemic therapies, potentially improving overall outcomes.
• Toxicity profiles for SBRT in this setting appear acceptable.

Conclusions:

• Local ablative therapy, including SBRT, shows promise for managing oligoprogressive disease in metastatic patients.
• Further prospective studies are crucial to establish definitive treatment guidelines.
• SBRT represents a potential advancement in overcoming treatment resistance in selected patients.